Log book

The Long Road for Oligonucleotide Therapeutics

7 June 2019 | Alcim's articles

Alcimed, an innovation and new business consulting firm, highlights the race for oligonucleotide therapeutics to catch peptides and discusses the current limitations for its widespread therapeutic use. March 22, 2019. Peptide vs Oligonucleotides: Iterative vs Exploratory Innovation Over the last 30 years, peptide technologies have gone from the forefront of innovative biotech to a standard […]

Read more